PrysmNet a polyp refining system using salience and multimodal guidance for reproducible cross domain segmentation - Top-Institutions - MDSpire

PrysmNet a polyp refining system using salience and multimodal guidance for reproducible cross domain segmentation

  • By

  • Junbo Xiao

  • Yi Han

  • Lei Wang

  • Ying Li

  • Xiaotong Wang

  • Shizhe Li

  • Jun Yi

  • Yu Wu

  • Xiaowei Liu

  • January 21, 2026

  • 0 min

Share

Top Institutions in Gastroenterology

Brief introduction explaining scope and methodology.

  • #1

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Gastroenterology
    • Oncology
    • Biomedical Engineering

  • #2

    Johns Hopkins University
    Johns Hopkins University

    Baltimore, MD

    Key Differentiators

    • Gastroenterology
    • Computer Science
    • Biomedical Engineering

  • #3

    Massachusetts General Hospital / Harvard Medical School
    Massachusetts General Hospital / Harvard Medical School

    Boston, MA

    Key Differentiators

    • Gastroenterology
    • Oncology
    • Radiology

  • #4

    University of California, San Diego (UCSD)
    University of California, San Diego (UCSD)

    San Diego, CA

    Key Differentiators

    • Gastroenterology
    • Computer Science
    • Biomedical Engineering

  • #5

    Imperial College London
    Imperial College London

    London, N/A

    Key Differentiators

    • Gastroenterology
    • Biomedical Engineering
    • Computer Science

Original Source(s)

PrysmNet a polyp refining system using salience and multimodal guidance for reproducible cross domain segmentation

  • by Junbo Xiao, Yi Han, Lei Wang, Ying Li, Xiaotong Wang, Shizhe Li, Jun Yi, Yu Wu, Xiaowei Liu

  • January 21, 2026

Related Content

Association of Socioeconomic Status and Mental Health History with Colorectal Cancer Risk: A National Nested Case-Control Analysis

Immune microenvironment evolution across the serrated neoplasia pathway and its relevance to immunotherapy

This Week’s Biopharma News: Amgen Deepens US Manufacturing Push

The company adds $300 million to its Puerto Rico biologics site as Pfizer reports Phase 3 myeloma data, J&J advances a dual-pathway IBD antibody, and BioNTech streamlines production

  • May 12, 2026

  • 7 min